NIH's translational center scores first drug acquisition by pharma | Higher Education and academic research |

Agency says success of new molecule for sickle cell disease shows its drug development model is working.

For the first time, a drug being developed in part by a controversial new National Institutes of Health (NIH) center aimed at speeding drug development has been picked up by a major pharmaceutical company. Baxter International has acquired the biotech company developing Aes-103, a small molecule for treating sickle cell disease. (...) - By Jocelyn Kaiser, Science, 9 July 2014

Via Julien Hering, PhD